Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Adenocarcinoma
This phase 2 randomized clinical trial assesses the safety and efficacy of durvalumab with and without tremelimumab for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.